ClinicalTrials.Veeva

Menu

MAsS Scan as a Predictor of Morbidity and Mortality in Patients With Liver Disease

The University of Chicago logo

The University of Chicago

Status

Enrolling

Conditions

Liver Diseases

Study type

Observational

Funder types

Other

Identifiers

NCT05264051
IRB21-0900

Details and patient eligibility

About

The purpose of the study is to study the muscle assessment score (MAsS, utilizing MRI, as an objective measure of frailty and muscle composition to serve as a predictor of morbidity and mortality in patients with liver disease.

Full description

Prospective study of patients seen at the Univ. of Chicago Medical Center hospital and ambulatory clinics. The assessment of the MAsS score will require an additional 8-10 minutes in the MRI for each patient already undergoing MRI exam.

Four groups of pts. who are already scheduled for MRI for routine clinical purposes will be evaluated.

  1. Pts. hospitalized with acute hepatic decompensation for whom MRI is otherwise indicated for clinical evaluation.
  2. Pts. with hepatobiliary neoplasia
  3. Pts.undergoing transjugular portosystemic shunt (TIPS) placement
  4. Pts. with chronic liver disease undergoing magnetic resonance elastography for routine monitoring

Enrollment

1,200 estimated patients

Sex

All

Ages

18+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  • Patients who are already scheduled for an MRI for routine clinical purposes will be evaluated

Exclusion criteria

  • <18 yrs. of age

Trial contacts and locations

1

Loading...

Central trial contact

Omar Jamil, MD; Maria Newsome

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2026 Veeva Systems